 Connection
David Orlicky to Cholangitis, Sclerosing
This is a "connection" page, showing publications David Orlicky has written about Cholangitis, Sclerosing.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.546 |
|
|
|
-
Shearn CT, Anderson AL, Miller CG, Noyd RC, Devereaux MW, Balasubramaniyan N, Orlicky DJ, Schmidt EE, Sokol RJ. Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury. Hepatol Commun. 2023 01 01; 7(1):e0020.
Score: 0.192
-
Gao RY, Shearn CT, Orlicky DJ, Battista KD, Alexeev EE, Cartwright IM, Lanis JM, Kostelecky RE, Ju C, Colgan SP, Fennimore BP. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis. Mucosal Immunol. 2021 03; 14(2):479-490.
Score: 0.164
-
Shearn CT, Orlicky DJ, Petersen DR. Dysregulation of antioxidant responses in patients diagnosed with concomitant Primary Sclerosing Cholangitis/Inflammatory Bowel Disease. Exp Mol Pathol. 2018 02; 104(1):1-8.
Score: 0.135
-
Shearn CT, Anderson AL, Devereaux MW, Koch SD, Larsen LD, Spencer LA, Orlicky DJ, Colgan SP, Steiner CA, Sokol RJ. Overexpression of TNFa in TNF?ARE+/- mice increases hepatic periportal inflammation and alters bile acid signaling in mice. Hepatol Commun. 2024 Dec 01; 8(12).
Score: 0.055
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|